In-house Manufacturing Facility
Two years of gene therapy manufacturing expertise
First GCTP/cGMP/PICS GMP complied manufacturing facility with 200L bioreactor completed Mar 2017
The “Manufacturing License for Cell & Gene Therapy Products” applied July 2018
Benefits of in-house manufacturing
Highly cost efficient without the out-licensing to the major pharmaceutical company
More controllable and flexibility
Capacity
Life Innovation Center based in Kanagawa
Current capacity: one 200L bioreactor
Plan to expand mfg process to 2nd and 3rd facility
